A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

NeoDynamics Will Be Granted Another European Patent for Its Pulse Biopsy Tools

NeoDynamics AB (Spotlight Stock Market: NEOD), a MedTech company dedicated to advancing diagnosis and care of breast cancer, today announces that the European Patent Office (EPO) has issued a Communication under Rule 71(3) EPC (Notice of Allowance) and intends to grant a European patent for their pulse biopsy tools, including a multi-purpose driver supporting several different needle options.

NeoDynamics notes the decision will be published in the European Patent Bulletin, once the requirements concerning the translation of the claims and payment of all fees are fulfilled by NeoDynamics.

“This is very exciting and supports our launch of the pulse biopsy system NeoNavia*, including three-needle options for all ultrasound, led biopsy procedures. This will reinforce our patent position in Europe. We continue to develop our portfolio of proprietary assets to further expand our business opportunities and to support our product.”, says Anna Eriksrud, CEO NeoDynamics.

She concluded, “The pioneering biopsy system has already gained significant interest, and we have managed to receive the first commercial orders, despite the challenging business environment following the pandemic. Ultrasound-guided biopsy in breast and axilla is perceived as critical to ensure an early and adequate diagnosis and ultimately improve patient outcomes”.

*NeoDynamics receives first UK order of pulse biopsy system NeoNavia in November of 2020.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy